Biomedical Engineering Reference
In-Depth Information
fully, this will lead to the identification of the new superdrug that will inhibit NF-
κ
B
without inducing severe side effects.
ACKNOWLEDGMENTS
Sebo Withoff is supported by National Institutes of Health (NIH) grants to IMV and
by a fellowship of the Catharina Foundation. Vinay Tergaonkar
is supported by a
career development fellowship from the Leukemia and Lymphoma Society. Inder
M. Verma is an American Cancer Society Professor of Molecular Biology supported
in part by grants from NIH, the Larry L. Hillblom Foundation, Inc., the Lebensfeld
Foundation, the Wayne and Gladys Valley Foundation, the H.N. and Frances C.
Berger Foundation, Merck Research Laboratories, and the March of Dimes.
REFERENCES
[1]
Shoelson, S.E., Lee, J., and Yuan, M., Inflammation and the IKKβ/IκB/NF-kappaB
axis in obesity- and diet-induced insulin resistance,
Int. J. Obes. Relat. Metab. Disord.,
27 Suppl 3, S49, 2003.
[2]
Mattson, M.P. and Camandola, S., NF-kappaB in neuronal plasticity and neurode-
generative disorders,
J. Clin. Invest.,
107, 247, 2001.
[3]
Li, Q., Withoff, S., and Verma, I.M., Inflammation-associated cancer: NF-kappaB is
the lynchpin,
Trends Immunol.,
26, 318, 2005.
[4]
Prigent, M., Barlat, I., Langen, H. et al., IκBα and IκBα/NF-kappaB complexes are
retained in the cytoplasm through interaction with a novel partner, RasGAP SH3-
binding protein 2,
J. Biol. Chem.,
275, 36441, 2000.
[5]
Rocha, S., Campbell, K.J., and Perkins, N.D., p53- and MDM2-independent repres-
sion of NF-kappaB transactivation by the ARF tumor suppressor,
Mol. Cell,
12, 15,
2003.
[6]
Rocha, S., Garrett, M.D., Campbell, K.J. et al., Regulation of NF-kappaB and p53
through activation of ATR and Chk1 by the ARF tumour suppressor,
Embo J.,
24,
1157, 2005.
[7]
Garkavtsev, I., Kozin, S.V., Chernova, O. et al., The candidate tumour suppressor
protein ING4 regulates brain tumour growth and angiogenesis,
Nature,
428, 328,
2004.
[8]
Webster, G.A. and Perkins, N.D., Transcriptional cross talk between NF-kappaB and
p53,
Mol. Cell. Biol.,
19, 3485, 1999.
[9]
Tergaonkar, V., Pando, M., Vafa, O. et al., p53 stabilization is decreased upon NF-
kappaB activation: A role for NF-kappaB in acquisition of resistance to chemotherapy,
Cancer Cell,
1, 493, 2002.
[10]
Gill, G., SUMO and ubiquitin in the nucleus: Different functions, similar mecha-
nisms?
Genes Dev.,
18, 2046, 2004.
[11]
Bouras, T., Fu, M., Sauve, A.A. et al., SIRT1 deacetylation and repression of p300
involves lysine residues 1020/1024 within the cell cycle regulatory domain 1,
J. Biol.
Chem.,
280, 10264, 2005.
[12]
O'Connor, W., Jr., Harton, J.A., Zhu, X. et al., Cutting edge: CIAS1/cryopy-
rin/PYPAF1/NALP3/CATERPILLER 1.1 is an inducible inflammatory mediator with
NF-kappaB suppressive properties,
J. Immunol.,
171, 6329, 2003.
